Phaseline

Companies › Implicit Bioscience

Implicit Bioscience: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Cardiovascular, Respiratory; next expected readout Mar 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ic14 (IC14)
Monocyte differentiation antigen CD14 inhibitor
CD14Phase 2Acute Respiratory Distress Syndrome; Acute Decompensated Heart Failure; STEMIMar 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06556810Ic14 (IC14)Phase 1Acute Decompensated Heart FailureCardiovascularApr 2026
NCT06678074Ic14 (IC14)Phase 1STEMICardiovascularJun 2026
NCT06513949Ic14 (IC14)Phase 2Acute Respiratory Distress SyndromeRespiratoryMar 2029

Targets

CD14 (1)

Companies with the same targets

–

Companies built like this

PPD Development, LP Connect Biopharm Abcentra Aqualung Therapeutics Upstream Bio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.